{
    "clinical_study": {
        "@rank": "37085", 
        "brief_summary": {
            "textblock": "To explore the safety of orally delivered rhIL-11 in patients with mild to moderate\n      left-sided ulcerative colitis.\n\n      To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples\n      and in colonic biopsy tissue samples."
        }, 
        "brief_title": "Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis", 
        "condition": [
            "Ulcerative Colitis", 
            "Inflammatory Bowel Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented, signed informed consent to participate in this study\n\n          -  Age greater than or equal to 18 years\n\n          -  Documented diagnosis of ulcerative colitis by standard clinical criteria, including\n             endoscopy (either flexible sigmoidoscopy or colonoscopy, sufficient to define the\n             proximal limit of disease) with biopsy\n\n        Exclusion Criteria:\n\n          -  Crohn's disease\n\n          -  Ulcerative proctitis\n\n          -  Ulcerative colitis extending beyond the splenic flexure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 5, 2002", 
        "id_info": {
            "nct_id": "NCT00038922", 
            "org_study_id": "3067K5-114"
        }, 
        "intervention": {
            "intervention_name": "rhIL-11", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Oprelvekin"
        }, 
        "keyword": [
            "Left-Sided", 
            "Ulcerative", 
            "Colitis"
        ], 
        "lastchanged_date": "May 17, 2006", 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038922"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2006"
    }, 
    "geocoordinates": {}
}